To examine the effects of triple beaded mixed amphetamine salts (TB MAS) on ADHD and executive dysfunction symptoms throughout the day in adults with DSM-5 ADHD.
Method:
This was a 6 week, single-blind, placebo-lead in trial of TB MAS (12.5–37.5 mg/day); all participants received 2 weeks of single-blind placebo); one individual was a placebo responder and was discontinued. One of these 18 dropped after 1 week on 12.5 mg/day, while all others completed the trial and received 37.5 mg/day TB MAS.
Results:
There were significant effects of TB MAS on all clinical measures, including investigator overall symptoms (AISRS); self-report overall (ASRS), time-sensitive ADHD (TASS) scores throughout the day, impairment (CGI) and executive function scores (BRIEF-A). TB MAS was generally well tolerated.
Conclusions:
This study extends prior findings of TB MAS to adults with DSM-5 ADHD; it further re-validates findings of efficacy of TB MAS throughout the day.
AdlerL. A.AlperinS.LeonT.FaraoneS. V. (2017). Pharmacokinetic and pharmacodynamic properties of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 27(2), 196–199. https://doi.org/10.1089/cap.2016.0121
2.
AdlerL. A.FaraoneS. V.SaroccoP.AtkinsN.KhachatryanA. (2019). Establishing US norms for the adult ADHD self-report scale (ASRS-v1.1) and characterising symptom burden among adults with self-reported ADHD. International Journal of Clinical Practice, 73(1), e13260. https://doi.org/10.1111/ijcp.13260
3.
AdlerL. A.LynchL. R.ShawD. M.WallaceS. P.CiranniM. A.BriggieA. M.KulagaA.O’DonnellK. E.FaraoneS. V. (2011). Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgraduate Medicine, 123(5), 71–79. https://doi.org/10.3810/pgm.2011.09.2461
4.
AdlerL. A.ShawD. M.SpencerT. J.NewcornJ. H.SittD. J.MorrillM.DavidowJ. V.GlattS. J.FaraoneS. V. (2011). Reliability and validity of the time-sensitive ADHD symptom scale in adults. Comprehensive Psychiatry, 52(6), 769–773. https://doi.org/10.1016/j.comppsych.2010.12.002
5.
AdlerL. A.SpencerT.FaraoneS. V.KesslerR. C.HowesM. J.BiedermanJ.SecnikK. (2006). Validity of pilot adult ADHD self- report scale (ASRS) to rate adult ADHD symptoms. Annals of Clinical Psychiatry, 18(3), 145–148. https://doi.org/10.1080/1040123060080107726
6.
AdlerL. A.ZimmermanB.StarrH. L.SilberS.PalumboJ.OrmanC.SpencerT. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology, 29(3), 239–247. https://doi.org/10.1097/JCP.0b013e3181a390ce
7.
AdlerL.CohenJ. (2004). Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27(2), 187–201. https://doi.org/10.1016/j.psc.2003.12.003
8.
AdlerL.ShawD.AlperinS. (2015). ADHD diagnostic and symptom assessment scales for adults. In AdlerL.SpencerT.WilensT. (Eds.), Attention-deficit hyperactivity disorder in adults and children (pp. 224–232). Cambridge University Press.
9.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Author.
10.
BarkleyR. A. (Ed.). (2005). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed.). Guilford Press.
11.
BiedermanJ.FitzgeraldM.SpencerT. J.AdlerL. A.AbramsJ.BiedermanI.FaraoneS. V. (2020). Informativeness of self-reports of ADHD symptoms in monitoring response to stimulant treatment in clinically referred adults with ADHD. Journal of Attention Disorders, 24(3), 420–424. https://doi.org/10.1177/1087054718776425
12.
BiedermanJ.PettyC. R.FriedR.DoyleA. E.SpencerT.SeidmanL. J.GrossL.PoetzlK.FaraoneS. V. (2007). Stability of executive function deficits into young adult years: A prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatrica Scandinavica, 116(2), 129–136. https://doi.org/10.1111/j.1600-0447.2007.01008.x
13.
BrownT. E.ChenJ.RobertsonB. (2022). Improved executive function in adults diagnosed with attention-deficit/ hyperactivity disorder as measured by the brown attention-deficit disorder scale following treatment with SHP465 mixed amphetamine salts extended-release: post hoc analyses from 2 randomized, placebo-controlled studies. Journal of Attention Disorders, 26(2), 256–266. https://doi.org/10.1177/1087054720961819
14.
CallenE. F.ClayT. L.AlaiJ.GoodmanD. W.AdlerL. A.ShieldsJ.FaraoneS. V. (2023). Progress and pitfalls in the provision of quality care for adults with attention deficit hyperactivity disorder in primary care. Journal of Attention Disorders, 27(6), 575–582. https://doi.org/10.1177/10870547231155875
15.
CorteseS.AdamoN.Del GiovaneC.Mohr-JensenC.HayesA. J.CarucciS.AtkinsonL. Z.TessariL.BanaschewskiT.CoghillD.HollisC.SimonoffE.ZuddasA.BarbuiC.PurgatoM.SteinhausenH. C.ShokranehF.XiaJ.CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
FaraoneS. V.BuitelaarJ. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child & Adolescent Psychiatry, 19(4), 353–364. https://doi.org/10.1007/s00787-009-0054-3
18.
FaraoneS. V.NewcornJ. H.CiprianiA.BrandeisD.KaiserA.HohmannS.HaegeA.CorteseS. (2022). Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: A systematic review and meta-analysis. Molecular Psychiatry, 27(1), 212–219. https://doi.org/10.1038/s41380-021-01134-w
19.
FaraoneS. V.SilversteinM. J.AntshelK.BiedermanJ.GoodmanD. W.MasonO.NierenbergA. A.RostainA.SteinM. A.AdlerL. A. (2019). The adult ADHD quality measures initiative. Journal of Attention Disorders, 23(10), 1063–1078. https://doi.org/10.1177/1087054718804354
20.
FrankeB.MicheliniG.AshersonP.BanaschewskiT.BilbowA.BuitelaarJ. K.CormandB.FaraoneS. V.GinsbergY.HaavikJ.KuntsiJ.LarssonH.LeschK. P.Ramos-QuirogaJ. A.RéthelyiJ. M.RibasesM.ReifA. (2018). Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology, 28(10), 1059–1088. https://doi.org/10.1016/j.euroneuro.2018.08.001
21.
FredriksenM.DahlA. A.MartinsenE. W.KlungsøyrO.HaavikJ.PeleikisD. E. (2014). Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity. European Neuropsychopharmacology, 24(12), 1873–1884. https://doi.org/10.1016/j.euroneuro.2014.09.013
22.
FrickG.YanB.AdlerL. A. (2020). Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: Results of a phase 3, double-blind, randomized, forced-dose trial. Journal of Attention Disorders, 24(3), 402–413. https://doi.org/10.1177/1087054717696771
23.
GinsbergL.KaticA.AdeyiB.DirksB.BabcockT.LasserR.SchecknerB.AdlerL. A. (2011). Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Current Medical Research and Opinion, 27(6), 1097–1107. https://doi.org/10.1185/03007995.2011.567256
24.
GrayS.WolteringS.MawjeeK.TannockR. (2014). The adult ADHD self-report scale (ASRS): Utility in college students with attention-deficit/hyperactivity disorder. PeerJ, 2, e324. https://doi.org/10.7717/peerj.324
25.
GuyW. (1976). Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No. 76–338 (pp. 217–222). National Institute of Mental Health.
26.
KesslerR. C.AdlerL.BarkleyR.BiedermanJ.ConnersC. K.DemlerO.FaraoneS. V.GreenhillL. L.HowesM. J.SecnikK.SpencerT.UstunT. B.WaltersE. E.ZaslavskyA. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. American Journal of Psychiatry, 163(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716
27.
KesslerR. C.GreenJ. G.AdlerL. A.BarkleyR. A.ChatterjiS.FaraoneS. V.FinkelmanM.GreenhillL. L.GruberM. J.JewellM.RussoL. J.SampsonN. A.Van BruntD. L. (2010). Structure and diagnosis of adult attention-deficit/hyperactivity disorder: Analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scale. Archives of General Psychiatry, 67(11), 1168–1178. https://doi.org/10.1001/archgenpsychiatry.2010.146
28.
MeunierJ.OberdhanD.M’HariM.CreelK.AdamsJ.AdlerL. (2021, January). Measurement Properties and Clinically Meaningful Change of the adult ADHD investigator symptom rating scale (AISRS) [Paper presentation]. Poster at the Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD). Tuscon, AZ.
29.
PosnerK.BrownG. K.StanleyB.BrentD. A.YershovaK. V.OquendoM. A.CurrierG. W.MelvinG. A.GreenhillL.ShenS.MannJ. J. (2011). The Columbia-suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277. https://doi.org/10.1176/appi.ajp.2011.10111704
30.
RothR. M.IsquithP. K.GioiaG. A. (2005). Behavior rating inventory of executive function-adult version (BRIEF-A). Psychological Assessment Resources.
31.
SheehanD. V.LecrubierY.SheehanK. H.AmorimP.JanavsJ.WeillerE.HerguetaT.BakerR.DunbarG. C. (1998). The mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59 Suppl20, 22–33.
32.
SilversteinM. J.AlperinS.FaraoneS. V.KesslerR. C.AdlerL. A. (2018). Test-retest reliability of the adult ADHD self-report scale (ASRS) v1.1 screener in non-ADHD controls from a primary care physician practice. Family Practice, 35(3), 336–341. https://doi.org/10.1093/fampra/cmx115
33.
SilversteinM. J.FaraoneS. V.AlperinS.BiedermanJ.SpencerT. J.AdlerL. A. (2018). How informative are self-reported adult attention-deficit/hyperactivity disorder symptoms? An examination of the agreement between the adult attention-deficit/hyperactivity disorder self-report scale V1.1 and adult attention-deficit/hyperactivity disorder investigator symptom rating scale. Journal of Child and Adolescent Psychopharmacology, 28(5), 339–349. https://doi.org/10.1089/cap.2017.0082
34.
SilversteinM. J.FaraoneS. V.AlperinS.LeonT. L.BiedermanJ.SpencerT. J.AdlerL. A. (2019). Validation of the expanded versions of the adult ADHD self-report scale v1.1 symptom checklist and the adult ADHD investigator symptom rating scale. Journal of Attention Disorders, 23(10), 1101–1110. https://doi.org/10.1177/1087054718756198
35.
SilversteinM. J.FaraoneS. V.LeonT. L.BiedermanJ.SpencerT. J.AdlerL. A. (2020). The relationship between executive function deficits and DSM-5-defined ADHD symptoms. Journal of Attention Disorders, 24(1), 41–51. https://doi.org/10.1177/1087054718804347
36.
SpencerT. J.AdlerL. A.MeihuaQ. I. A. O.SaylorK. E.BrownT. E.HoldnackJ. A.SchuhK. J.TrzepaczP. T.KelseyD. K. (2010). Validation of the adult ADHD investigator symptom rating scale (AISRS). Journal of Attention Disorders, 14(1), 57–68. https://doi.org/10.1177/1087054709347435
37.
SpencerT. J.AdlerL. A.WeislerR. H.YouchaS. H. (2008). Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. Journal of Clinical Psychiatry, 69(9), 1437–1448. https://doi.org/10.4088/jcp.v69n0911
UstunB.AdlerL. A.RudinC.FaraoneS. V.SpencerT. J.BerglundP.GruberM. J.KesslerR. C. (2017). The World Health Organization adult attention-deficit/hyperactivity disorder self-report screening scale for dsm-5.-5. JAMA Psychiatry, 74(5), 520–527. https://doi.org/10.1001/jamapsychiatry.2017.0298
40.
WeislerR. H.GreenbaumM.ArnoldV.YuM.YanB.JaffeeM.RobertsonB. (2017). Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs, 31(8), 685–697. https://doi.org/10.1007/s40263-017-0455-7
